Valvular & structural heart disease
Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement: The PARTNER 3 Trial
Authors' conclusion
TAVR with the SAPIEN 3 valve led to similar 5-year clinical and health status outcomes compared with SAVR, irrespective of annular size.
Study context
- Population
- Low-risk patients with severe, symptomatic aortic stenosis (AS); stratified by CT angiography-derived annular area (small ≤430 mm²; large >430 mm²)293 small, 632 large annuli
- Participants
- 925 patients
- Comparison
- Transcatheter aortic valve replacement (TAVR) vs surgical aortic valve replacement (SAVR) by aortic annular size
- Primary endpoint
- Composite of:
- Death
- Stroke
- Rehospitalization
- Follow-up
- 5 years
Methodological detailssubgroup analysis by annular size
- Subgroup analysis by annular size
Primary result
As reported in the abstract
Death, stroke, or rehospitalization by annular size
TAVR vs SAVROdds ratio (95% CI)
Small annuli: 21.2% vs 31.0%
0.60(0.35–1.02)
Large annuli: 23.5% vs 25.5%
0.90(0.62–1.29)
Further findings
Bioprosthetic valve failure · 5 years
- Similar and low, without effect modification by annular size
Health status · 5 years
- Similar between treatment modalities across annulus strata
- P for interaction = 0.12
Original publication
Impact of Aortic Annulus Size on Outcomes After Aortic Valve Replacement: The PARTNER 3 Trial. JACC Cardiovasc Interv. Published 27 July 2026. doi:10.
Summarised from the published abstract; every number is checked against it